Printer Friendly

CELL GENESYS, INC. FILES FOR INITIAL PUBLIC OFFERING OF COMMON STOCK

 FOSTER CITY, Calif., Jan. 4 /PRNewswire/ -- Cell Genesys, Inc. today announced that it has filed an amended registration statement with the Securities and Exchange Commission relating to the company's proposed initial public offering of 3 million shares of common stock. All shares offered are to be sold by the company. It is currently anticipated that the initial public offering price will be between $9 and $11 per share. The shares will be offered by an underwriting group managed by Robertson, Stephens & Company, Invemed Associates, Inc. and Oppenheimer & Company Inc.
 Cell Genesys is a leader in the application of gene targeting to the development of human therapeutic healthcare products. Gene targeting is a new cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, human therapeutic protein products, and human monoclonal antibody products.
 A copy of the preliminary prospectus relating to this offering can be obtained from Robertson, Stephens & Company, One Embarcadero Center, Suite 3100, San Francisco, Calif. 94111, 415-781-9700; Invemed Associates Inc., 375 Park Avenue, New York, N.Y. 10152, 212-421-2500, or Oppenheimer & Co., Inc., Oppenheimer Tower, One World Financial Center, New York, N.Y. 10281, 212-667-7000.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
 -0- 1/4/93
 /CONTACT: Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys, Inc., 415-358-9600/


CO: Cell Genesys, Inc. ST: California IN: MTC SU: OFR

LR-TS -- NY012 -- 1184 01/04/93 09:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1993
Words:350
Previous Article:MCDONNELL DOUGLAS CORPORATION AGREES TO SELL MCDONNELL DOUGLAS INFORMATION SYSTEMS INTERNATIONAL
Next Article:IMC FERTILIZER COMPLETES PURCHASE OF CONSERV PHOSPHATE CHEMICAL UNIT
Topics:


Related Articles
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
CELL GENESYS REPORTS SECOND QUARTER RESULTS
CELL GENESYS AND CELLPRO COLLABORATE ON ANTI-HIV T CELLS FOR AIDS
CELL GENESYS FILES FOR STOCK OFFERING
CELL GENESYS COMPLETES SECONDARY STOCK OFFERING
CELL GENESYS ADOPTS STOCKHOLDER RIGHTS PLAN
Cell Genesys Reports Third Quarter Results Fourth Consecutive Quarter of Income in Gene Therapy Business.
Cell Genesys Reports Third Quarter Results.
Cell Genesys Announces Completion of Common Stock Offering and Exercise of Underwriters' Over-Allotment Option.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters